

# Sang-Hee Cho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6221731/publications.pdf>

Version: 2024-02-01

39  
papers

1,133  
citations

623734

14  
h-index

434195

31  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2382  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 76-87.	21.4	377
2	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2903-2913.	1.6	154
3	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671.	10.7	107
4	Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 589-595.	2.3	66
5	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 300-312.	3.0	48
6	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> , 2021, 160, 1164-1178.e6.	1.3	36
7	IL-12 Enhances Immune Response by Modulation of Myeloid Derived Suppressor Cells in Tumor Microenvironment. <i>Chonnam Medical Journal</i> , 2019, 55, 31.	0.9	35
8	Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). <i>Gastric Cancer</i> , 2021, 24, 156-167.	5.3	29
9	Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 541-6.	1.3	28
10	Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites. <i>Journal of Gastric Cancer</i> , 2019, 19, 301.	2.5	24
11	A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study. <i>Oncologist</i> , 2015, 20, 1432-1439.	3.7	21
12	Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 246-253.	3.0	21
13	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 165-177.	1.7	20
14	Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. <i>International Journal of Cancer</i> , 2022, 150, 2038-2045.	5.1	19
15	TAp73 inhibits cell invasion and migration by directly activating KAI1 expression in colorectal carcinoma. <i>Cancer Letters</i> , 2018, 415, 106-116.	7.2	18
16	Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. <i>Cancer Science</i> , 2020, 111, 3268-3278.	3.9	15
17	Polymyositis and myocarditis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2009, 90, 113-116.	1.6	14
18	Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2157-2166.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Association between ALDH2 and ADH1B Polymorphisms and the Risk for Colorectal Cancer in Koreans. <i>Cancer Research and Treatment</i> , 2021, 53, 754-762.	3.0	14
20	Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status. <i>BMC Cancer</i> , 2014, 14, 824.	2.6	13
21	FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition. <i>Cancer Research and Treatment</i> , 2017, 49, 766-777.	3.0	12
22	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2020, 19, e140-e150.	2.3	9
23	Association between ALDH2 polymorphism and esophageal cancer risk in South Koreans: a case-control study. <i>BMC Cancer</i> , 2021, 21, 254.	2.6	8
24	Impact of <i>UGT1A1</i> genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 4669-4678.	3.9	8
25	Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. <i>Oncologist</i> , 2017, 22, 293-303.	3.7	5
26	Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy. <i>Medicine (United States)</i> , 2020, 99, e23173.	1.0	5
27	Association between <i>ALDH2</i> Polymorphism and Gastric Cancer Risk in a Korean Population. <i>Journal of Korean Medical Science</i> , 2020, 35, e148.	2.5	4
28	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4016-4016.	1.6	3
29	The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis. <i>Oncotarget</i> , 2017, 8, 66559-66568.	1.8	3
30	Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma. <i>Processes</i> , 2021, 9, 792.	2.8	1
31	The use of anticoagulants in terminal cancer patients admitted in hospice center.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21503-e21503.	1.6	1
32	Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 660-672.	1.7	1
33	Prognostic role of PD-L1 polymorphism according to MSI in colon cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14578-e14578.	1.6	0
34	Prospective multicenter study evaluating adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients: a KSWOG (Korean South West Oncology Group) study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9605-9605.	1.6	0
35	Follow-up data from a phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1 based chemoradiotherapy for advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 116-116.	1.6	0
36	The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15128-e15128.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Epithelial mesenchymal transition in an advanced BRAF mutation type colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 693-693.	1.6	0
38	Lymph node ratio as a clinical determinant for selecting adjuvant chemotherapy regimen in curative D2 resected gastric cancer.. Journal of Clinical Oncology, 2018, 36, 4034-4034.	1.6	0
39	Long-term outcomes after induction chemotherapy with docetaxel, cisplatin and 5-FU (TPF) followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal cancer.. Journal of Clinical Oncology, 2018, 36, e18008-e18008.	1.6	0